JP Morgan Chase
BHVN

JP Morgan Chase’s Biohaven Pharmaceutical Holding Company Ltd. BHVN Stock Holding History

JP Morgan Chase’s Portfolio BHVN Stock Details BHVN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-30,000
Closed -$4.17M – 7319
2021
Q3 		$4.17M Buy
+30,000
New +$3.75M ﹤0.01% 3187
2021
Q1 		– Sell
-200,000
Closed -$17.1M – 6597
2020
Q4 		$17.1M Buy
+200,000
New +$16.9M ﹤0.01% 1750
2019
Q3 		– Sell
-17,000
Closed -$723K – 6183
2019
Q2 		$723K Buy
+17,000
New +$958K ﹤0.01% 4039
2018
Q2 		– Sell
-7,000
Closed -$180K – 5911
2018
Q1 		$180K Buy
+7,000
New +$209K ﹤0.01% 4411

Other funds holding BHVN

LIP
Liontrust Investment Partners London, United Kingdom $6.8B AUM 23.31% 1-Year Est. Return
KCM
Knoll Capital Management Miami, Florida $214M AUM 62.74% 1-Year Est. Return
BC
Birchview Capital Burlington, Vermont $214M AUM 185.33% 1-Year Est. Return
BTI
Blue Trust Inc Alpharetta, Georgia $9.54B AUM 19.86% 1-Year Est. Return
FIA
FNY Investment Advisers New York $278M AUM 98.95% 1-Year Est. Return
IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return
MSCM
McElhenny Sheffield Capital Management Dallas, Texas $404M AUM 19.8% 1-Year Est. Return

JP Morgan Chase's BHVN Position: Q4 2022 in Review

JP Morgan Chase sold out of Biohaven Pharmaceutical Holding Company Ltd. (BHVN) in Q4 2022, closing a stake of 2,041,718 shares — an estimated $309M sold.

JP Morgan Chase first reported a position in BHVN in Q2 2017 and held it in 22 quarters. The position peaked at $309M in Q3 2022. 7 funds tracked by Wall St. Rank hold BHVN as of Q4 2022.

  • JP Morgan Chase reported no remaining Biohaven Pharmaceutical Holding Company Ltd. position as of Q4 2022 after selling out during the quarter.
  • JP Morgan Chase sold 2,041,718 Biohaven Pharmaceutical Holding Company Ltd. shares in Q4 2022, an estimated $309M.
  • JP Morgan Chase first reported a position in Biohaven Pharmaceutical Holding Company Ltd. in Q2 2017 and held it in 22 quarters.
  • JP Morgan Chase's Biohaven Pharmaceutical Holding Company Ltd. position peaked at $309M in Q3 2022.
  • 7 funds tracked by Wall St. Rank held Biohaven Pharmaceutical Holding Company Ltd. as of Q4 2022.

Based on JP Morgan Chase's 13F filing for Q4 2022, filed 13 Feb 2023.